Vaccine Development

Vaccines are arguably one of the best value medicines available to governments and national bodies in preventing rather than treating disease.   Vaccine Development is an activity that GRA identifies as a core area of expertise.   GRA has worked on a wide array of areas in the development of vaccines that include activities including discovery, R&D, process development, assay development and regulatory interactions with agencies.  Vaccines come in many forms – viral, bacterial, live attenuated, inactivated, VLP, recombinant and vector based.  All have their own idiosyncrasies & requirements to become a successful products.   Given the complexity of vaccines and their interaction with the immune system, appropriate assay development is a critical component of measuring vaccine potency, whether in the vial or the immune response from the patient.  GRA has many years experience of helping in the development of vaccine potency assays that include: TCID50, plaque based assays, immunofocus assays, flow cytometric assays, QPCR assays and ELISAs,

GRA has worked with a number of companies in the development of vaccines including Takeda Vaccines, FluGen & Themis Biosciences.  Our experience covers viral, bacterial, live attenuated, inactivated, VLP, recombinant and vector based products.  Diseases that GRA have experience of include:

• Dengue Fever
• Zika virus
• Influenza
• Enterovirus 71 (EV71 – Hand, Foot & Mouth)
• Typhoid
• Measles
• Meningitis B
• Hepatitis B
• Chikungunya
• Enterotoxigenic E. coli
• Group B Streptococcus (GBS)
• Anthrax
• Herpes Simplex Virus I/II (HSV)
• Japanese encephalitis